Fort Sheridan Advisors LLC Geron Corp Transaction History

Fort Sheridan Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 12, 2019	SELL	$1.15 - $1.59 $2,300 - $3,180	-2,000 Reduced 5.97%	31,500 $42,000
Q2 2019 Aug 14, 2019	BUY	$1.37 - $2.02 $8,220 - $12,120	6,000 Added 21.82%	33,500 $47,000
Q4 2018 May 13, 2019	BUY	$0.98 - $1.85 $26,950 - $50,875	27,500 New	27,500 $28,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Fort Sheridan Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Fort Sheridan Advisors LLC with notifications on news.